Moderna Therapeutics LLC has become one of the biopharmaceutical industry’s biggest unicorns – attracting billions of dollars in venture, partnership and grant funding – while revealing few details about its messenger RNA (mRNA) therapeutic platform. But the normally secretive company subjected its pipeline to public scrutiny during an appearance at the J.P. Morgan Healthcare Conference.
Scrip spoke with Moderna CEO Stephane Bancel about before and after the standing-room-only Jan. 9 J.P. Morgan presentation, which was...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
